<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>biopharmaceutical on FinanClub</title>
    <link>https://finan.club/tags/biopharmaceutical/</link>
    <description>Recent content in biopharmaceutical on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 16 Feb 2024 09:03:20 +0000</lastBuildDate><atom:link href="https://finan.club/tags/biopharmaceutical/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>CRSP</title>
      <link>https://finan.club/us/crsp/</link>
      <pubDate>Fri, 16 Feb 2024 09:03:20 +0000</pubDate>
      
      <guid>https://finan.club/us/crsp/</guid>
      <description>score:31
Chances: CRISPR Therapeutics has shown improving price performance, earning an upgrade to its IBD Relative Strength Rating. The company is focused on creating transformative gene-based medicines for serious diseases, and has announced conditional marketing authorization for its gene edited therapy, CASGEVY. Risks: The company doesn&amp;rsquo;t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.</description>
    </item>
    
    <item>
      <title>ALKS</title>
      <link>https://finan.club/us/alks/</link>
      <pubDate>Fri, 16 Feb 2024 09:02:33 +0000</pubDate>
      
      <guid>https://finan.club/us/alks/</guid>
      <description>score:-21
Chances: Alkermes stock saw its Relative Strength Rating improve from 69 to 75, indicating a potential rebound in the stock&amp;rsquo;s performance. The company&amp;rsquo;s earnings and revenues outpaced estimates in the fourth quarter of 2023, driven by strong growth in proprietary products. Robust revenue growth and strategic focus are likely to propel Alkermes into 2024, indicating positive prospects for the company.</description>
    </item>
    
    <item>
      <title>ARWR</title>
      <link>https://finan.club/us/arwr/</link>
      <pubDate>Thu, 04 Jan 2024 09:10:03 +0000</pubDate>
      
      <guid>https://finan.club/us/arwr/</guid>
      <description>score:114
Chances: The company has successfully priced an underwritten registered offering, indicating strong investor interest and potential for significant capital influx. The filing of an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB demonstrates progress in the company’s pipeline development.</description>
    </item>
    
    <item>
      <title>ROIV</title>
      <link>https://finan.club/us/roiv/</link>
      <pubDate>Wed, 27 Dec 2023 09:02:32 +0000</pubDate>
      
      <guid>https://finan.club/us/roiv/</guid>
      <description>score:2
Chances: Immunovant, Inc. announced that results from the initial cohort of patients in the Phase 2 clinical trial of batoclimab in Graves’ disease exceeded 50% response rates, indicating promising potential for the drug Risks: Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index (SRI-4) change of 4 at Week 52, indicating a setback in the drug&amp;rsquo;s development for this specific indication Score:2 chances characters count - risks characters count = 2</description>
    </item>
    
  </channel>
</rss>
